219 related articles for article (PubMed ID: 21765461)
1. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
[TBL] [Abstract][Full Text] [Related]
2. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
3. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
[TBL] [Abstract][Full Text] [Related]
5. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
[TBL] [Abstract][Full Text] [Related]
6. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.
Wu F; Peacock SO; Rao S; Lemmon SK; Burnstein KL
J Biol Chem; 2013 Feb; 288(8):5463-74. PubMed ID: 23281476
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
Liu Y; Wu X; Dong Z; Lu S
Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
[TBL] [Abstract][Full Text] [Related]
8. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
10. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
11. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.
Dar JA; Masoodi KZ; Eisermann K; Isharwal S; Ai J; Pascal LE; Nelson JB; Wang Z
J Steroid Biochem Mol Biol; 2014 Sep; 143():473-80. PubMed ID: 24662325
[TBL] [Abstract][Full Text] [Related]
13. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
[TBL] [Abstract][Full Text] [Related]
14. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
15. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.
Lu Y; Feng F; Yang Y; Gao X; Cui J; Zhang C; Zhang F; Xu Z; Qv J; Wang C; Zeng Z; Zhu Y; Yang Y
Cell Signal; 2013 Feb; 25(2):479-89. PubMed ID: 23153584
[TBL] [Abstract][Full Text] [Related]
16. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.
Tan JA; Bai S; Grossman G; Titus MA; Harris Ford O; Pop EA; Smith GJ; Mohler JL; Wilson EM; French FS
Mol Cell Endocrinol; 2014 Jan; 382(1):302-313. PubMed ID: 24103312
[TBL] [Abstract][Full Text] [Related]
20. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]